entertainment -WSS

entertainment

author：fashion 2025-08-12 08:25:40 - browse：12599

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Medicare Advantage overpayments discussion gets experts fired up

WSS

Alabama frozen embryo ruling has major implications for IVF clinics

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

In shift, Texas to cover initial consult for Afghan baby's gene therapy

6 phony surgeries that take placebo to the extreme

Alabama hospital puts IVF treatments on hold

American taxpayers paid $1.8 trillion in health care costs in 2022

hotspot

entertainment

explore

Bright Health sells Medicare Advantage business to Molina

Dario to buy mental health app maker Twill in cash and stock deal

Continuity nursing helped my family in our darkest PICU moments

Life science postdocs should get big pay hike, NIH panel says

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Dobbs anniversary: the lost opportunity of abortion as health care

Merck to acquire Harpoon Therapeutics for $680 million

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare inequities exacerbate Puerto Rico’s health disparities

hotspot

6 phony surgeries that take placebo to the extreme

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Ascension's ugly legal battle over care for poor patients in Texas

knowledge

focus

hotspot

focus